ストックスクリーナーアプリを入手
0.3468
7.10%
-0.0265
アフターアワーズ：
.35
0.0032
+0.92%
前日終値:
$0.3733
開ける：
$0.37
24時間の取引高:
698.86K
Relative Volume:
0.74
時価総額：
$20.22M
収益：
-
当期純損益:
$-123.46M
株価収益率:
-0.1339
EPS:
-2.59
ネットキャッシュフロー:
$-104.11M
1週間 パフォーマンス:
-6.27%
1か月 パフォーマンス:
+6.45%
6か月 パフォーマンス:
-80.30%
1年 パフォーマンス:
-89.92%
1日の値動き範囲:
$0.3216
$0.37
1週間の範囲:
$0.283
$0.40
52週間の値動き範囲:
$0.2806
$4.02
Bioatla Inc Stock (BCAB) Company Profile
BCAB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.3468 | 20.22M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-13 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-05-05 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-06-28 | 開始されました | ROTH Capital | Buy |
| 2021-05-05 | 再開されました | Credit Suisse | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-01-11 | 開始されました | BTIG Research | Buy |
| 2021-01-11 | 開始されました | Credit Suisse | Outperform |
| 2021-01-11 | 開始されました | JP Morgan | Overweight |
| 2021-01-11 | 開始されました | Jefferies | Buy |
すべてを表示
Bioatla Inc (BCAB) 最新ニュース
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
BioAtla price target lowered to $1 from $5 at Citizens JMP - TipRanks
BioAtla stock price target cut to $1 by Citizens JMP - Investing.com
BioAtla, Inc. (NASDAQ:BCAB) Q4 2024 Earnings Call Transcript - MSN
Companies Like BioAtla (NASDAQ:BCAB) Could Be Quite Risky - Yahoo Finance
BioAtla’s Earnings Call: Clinical Progress and Strategic Outlook - TipRanks
BioAtla stock price target cut to $10 at BTIG, retains Buy rating - Investing.com Canada
BioAtla stock price target cut to $10 at BTIG, retains Buy rating By Investing.com - Investing.com South Africa
BioAtla Inc. (BCAB) reports earnings - Quartz
BioAtla, Inc. SEC 10-K Report - TradingView
BioAtla, Inc. Reports 2024 Financial Results and Clinical Progress - TipRanks
Earnings call transcript: BioAtla Q4 2024 sees strategic cost cuts, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: BioAtla Q4 2024 sees strategic cost cuts, stock rises - Investing.com India
BioAtla announces restructuring, to cut over 30% of workforce - TipRanks
BioAtla reports Q4 Net loss ($14.9M) vs ($26.9M) last year - TipRanks
Bioatla IncAnnounces 30% Workforce Reduction - MarketScreener
BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress - The Manila Times
Earnings Outlook For BioAtla - Benzinga
BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings - Quantisnow
BioAtla, Inc. Announces Abstract Presentations at European Lung Cancer Congress and Mayo Clinic Symposium 2025 - Nasdaq
BioAtla Advances Cancer Research with Dual Presentations at Elite European and Mayo Clinic Conferences - Stock Titan
BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025 - Quantisnow
BioAtla (BCAB) Expected to Announce Quarterly Earnings on Tuesday - Defense World
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
BioAtla Awards Executive Bonuses and Stock Units - TipRanks
What Are You Thinking About Investing In BioAtla Inc (NASDAQ: BCAB) Stock? - stocksregister.com
BioAtla, Inc. (NASDAQ:BCAB) Short Interest Down 12.6% in February - Defense World
Bioatla stock hits 52-week low at $0.38 amid sharp decline By Investing.com - Investing.com South Africa
Bioatla stock hits 52-week low at $0.38 amid sharp decline - Investing.com UK
BioAtla Inc (BCAB) shows promising results - US Post News
Market Momentum Report: BioAtla Inc (BCAB)’s Negative Close at 0.45 - The Dwinnex
BioAtla Inc: Navigating a Turbulent Year, Up -88.84% from 52-Week Low - The InvestChronicle
BioAtla faces Nasdaq delisting over share price rule - MSN
BioAtla Inc (BCAB) Shares Down Despite Recent Market Volatility - The News Heater
Millennium Management LLC Reduces Stake in BioAtla Inc. - GuruFocus.com
Jane Street Group LLC Decreases Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla (NASDAQ:BCAB) Stock Price Down 6.1% – Here’s Why - Defense World
Bioatla stock hits 52-week low at $0.57 amid sharp decline - Investing.com
Fierce Biotech Layoff Tracker 2025: BioAtla implements 30% RIF; Nkarta cuts 53 roles - Fierce Biotech
BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
**BioAtla Updates Corporate Presentation in 8-K Filing** - Defense World
BioAtla Announces Registered Direct Offering to Advance Clinical Programs to Key Inflection PointsSan Diego, Calif., December 20, 2024 – BioAtla, Inc. (NASDAQ: BCAB), a global clinical-stage biotechnology company, disclosed on December 19, 2024, that - Defense World
Bioatla stock hits 52-week low at $1.02 amid market challenges - Investing.com Australia
BioAtla Secures $9.2M for Clinical Program Advancements - TipRanks
Bioatla Inc (BCAB) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):